Brokerages predict that Crispr Therapeutics AG (NASDAQ:CRSP) will post earnings per share (EPS) of $0.04 for the current quarter, according to Zacks. Four analysts have made estimates for Crispr Therapeutics’ earnings. The lowest EPS estimate is $0.01 and the highest is $0.07. Crispr Therapeutics reported earnings of ($0.92) per share during the same quarter last year, which indicates a positive year over year growth rate of 104.3%. The company is scheduled to issue its next earnings results on Monday, February 24th.
On average, analysts expect that Crispr Therapeutics will report full year earnings of $0.65 per share for the current year, with EPS estimates ranging from $0.59 to $0.71. For the next year, analysts expect that the business will post earnings of ($4.68) per share, with EPS estimates ranging from ($5.38) to ($3.67). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Crispr Therapeutics.
Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, October 28th. The company reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.95) by $3.35. The company had revenue of $211.93 million for the quarter, compared to analysts’ expectations of $6.32 million. Crispr Therapeutics had a negative return on equity of 2.60% and a negative net margin of 5.30%.
A number of equities analysts recently weighed in on CRSP shares. Wells Fargo & Co restated a “buy” rating on shares of Crispr Therapeutics in a report on Friday. Zacks Investment Research cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 30th. Chardan Capital reissued a “buy” rating and issued a $72.50 price objective on shares of Crispr Therapeutics in a research report on Monday, November 18th. Roth Capital boosted their price objective on shares of Crispr Therapeutics from $65.00 to $100.00 in a research note on Tuesday, November 19th. Finally, TheStreet upgraded shares of Crispr Therapeutics from a “d” rating to a “c” rating in a research note on Monday, October 28th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. Crispr Therapeutics has an average rating of “Buy” and a consensus price target of $69.54.
In related news, Director Pablo J. Cagnoni sold 7,500 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $55.00, for a total value of $412,500.00. Following the transaction, the director now owns 7,500 shares in the company, valued at approximately $412,500. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, President Rodger Novak sold 33,618 shares of the company’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $70.00, for a total transaction of $2,353,260.00. Following the completion of the transaction, the president now owns 33,618 shares in the company, valued at approximately $2,353,260. The disclosure for this sale can be found here. Insiders have sold a total of 56,118 shares of company stock valued at $3,620,760 in the last ninety days. Insiders own 21.40% of the company’s stock.
Several large investors have recently modified their holdings of the company. NEXT Financial Group Inc increased its stake in shares of Crispr Therapeutics by 915.0% during the third quarter. NEXT Financial Group Inc now owns 609 shares of the company’s stock worth $25,000 after purchasing an additional 549 shares during the period. Benjamin Edwards Inc. grew its holdings in Crispr Therapeutics by 96.4% in the 2nd quarter. Benjamin Edwards Inc. now owns 546 shares of the company’s stock valued at $26,000 after buying an additional 268 shares in the last quarter. Coastal Investment Advisors Inc. acquired a new position in Crispr Therapeutics in the 3rd quarter valued at $26,000. US Bancorp DE increased its position in Crispr Therapeutics by 553.7% during the 2nd quarter. US Bancorp DE now owns 621 shares of the company’s stock worth $29,000 after buying an additional 526 shares during the period. Finally, BSW Wealth Partners bought a new position in Crispr Therapeutics during the 2nd quarter worth $39,000. Institutional investors own 49.81% of the company’s stock.
Shares of NASDAQ:CRSP traded up $1.66 during midday trading on Monday, hitting $72.37. The stock had a trading volume of 892,934 shares, compared to its average volume of 703,877. Crispr Therapeutics has a 12 month low of $22.22 and a 12 month high of $74.00. The company has a quick ratio of 8.32, a current ratio of 8.32 and a debt-to-equity ratio of 0.06. The business’s 50-day simple moving average is $54.81 and its 200-day simple moving average is $47.38. The company has a market cap of $4.00 billion, a P/E ratio of -21.04 and a beta of 3.30.
About Crispr Therapeutics
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.
Featured Story: What is required to own or exchange cryptocurrency?
Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
